Otonomy Stock Forecast, Price & News

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

Is Otonomy a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy or view top-rated stocks.

How has Otonomy's stock price been impacted by COVID-19?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OTIC stock has decreased by 21.8% and is now trading at $2.05.
View which stocks have been most impacted by COVID-19.

Are investors shorting Otonomy?

Otonomy saw a increase in short interest in October. As of October 15th, there was short interest totaling 565,700 shares, an increase of 25.3% from the September 30th total of 451,600 shares. Based on an average daily volume of 346,600 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.1% of the company's stock are short sold.
View Otonomy's Short Interest.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Otonomy.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19). Otonomy had a negative trailing twelve-month return on equity of 72.42% and a negative net margin of 20,278.95%. During the same period in the prior year, the firm earned ($0.22) earnings per share.
View Otonomy's earnings history.

What price target have analysts set for OTIC?

2 Wall Street analysts have issued 1 year target prices for Otonomy's stock. Their forecasts range from $5.50 to $6.00. On average, they expect Otonomy's share price to reach $5.75 in the next twelve months. This suggests a possible upside of 180.5% from the stock's current price.
View analysts' price targets for Otonomy or view top-rated stocks among Wall Street analysts.

Who are Otonomy's key executives?

Otonomy's management team includes the following people:

• David A. Weber, President, Chief Executive Officer & Director
• Paul E. Cayer, Chief Financial & Business Officer
• Fabrice Piu, Vice President-Research & Preclinical Development
• Robert Michael Savel, Chief Technical Officer
• Alan C. Foster, Vice President-Research

Who are some of Otonomy's key competitors?

Some companies that are related to Otonomy include Albireo Pharma (ALBO), Evelo Biosciences (EVLO), Spero Therapeutics (SPRO), Flexion Therapeutics (FLXN), Longeveron (LGVN), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Rhythm Pharmaceuticals (RYTM), Aadi Bioscience (AADI), Aldeyra Therapeutics (ALDX), Thorne Healthtech (THRN), Provention Bio (PRVB), Mirum Pharmaceuticals (MIRM), CytomX Therapeutics (CTMX) and Foghorn Therapeutics (FHTX).
View all of OTIC's competitors.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (2.88%), BlackRock Inc. (1.41%), Dimensional Fund Advisors LP (1.34%), Point72 Asset Management L.P. (1.14%), Renaissance Technologies LLC (1.07%) and Geode Capital Management LLC (0.80%).
View institutional ownership trends for Otonomy.

Which institutional investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Advisers LP, Two Sigma Investments LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and BlackRock Inc..
View insider buying and selling activity for Otonomy or view top insider-selling stocks.

Which institutional investors are buying Otonomy stock?

OTIC stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Point72 Asset Management L.P., Two Sigma Securities LLC, Geode Capital Management LLC, and Barclays PLC.
View insider buying and selling activity for Otonomy or or view top insider-buying stocks.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.05.

How much money does Otonomy make?

Otonomy has a market capitalization of $116.20 million and generates $270 thousand in revenue each year. The biopharmaceutical company earns $-44.73 million in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Otonomy have?

Otonomy employs 56 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at [email protected], or via fax at 619-291-9190.